Place · Level 3 · Condition
Type 2 Diabetes & Prediabetes
中国 1.4 亿患者 · IR 三通路 · DiRECT 46% 缓解 · HbA1c / OGTT 解读 · 饮食 + 运动 + 药物完整谱
Story path
Chapter 1
T2D · what + epidemiology
T2D · what + epidemiology
Type 2 diabetes (T2D) = chronic hyperglycemia caused by insulin resistance + relatively insufficient secretion. Distinct from T1D, which is autoimmune β-cell destruction → absolute insulin deficiency.
Diagnostic criteria (ADA + Chinese Diabetes Society):
HbA1c ≥ 6.5% (glycated hemoglobin, reflects 3-month average glucose)or fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL) × two occasionsor OGTT 2 h glucose ≥ 11.1 mmol/L (200 mg/dL)or random glucose ≥ 11.1 mmol/L + hyperglycemia symptoms
Prediabetes:
HbA1c 5.7-6.4%or fasting 5.6-6.9 mmol/L (100-125 mg/dL, IFG)or OGTT 2 h 7.8-11.0 mmol/L (IGT)about 5-10% per year progress to T2D, but reversible
Epidemiology (China, IDF 2021 + Wang 2017 JAMA):
T2D prevalence 11.2% (~ 140 million patients), the largest in the worldprediabetes 35-50% (400-500 million nationwide)undiagnosed rate 50%+ — half of T2D patients do not know they have itannual healthcare cost ~ 200 billion CNY
Asian-phenotype specificities:
At the same BMI, T2D risk is 2-3× higher vs Europeans (Hu 2011 Lancet)"Lean T2D" — BMI < 25 can still develop disease; Asian diagnostic cutoffs should be at lower BMI (China ≥ 24 = overweight, vs Western ≥ 25)Mechanism: at the same BMI, visceral fat + insulin resistance + β-cell decline are all more pronounced
"Diabetes = a disease of the elderly" no longer holds:
T2D prevalence in Chinese 20-39 y/o is 5-8% (2020)Pediatric and adolescent T2D is rising sharply with obesity + UPFEarly-onset T2D has a larger lifespan impact (every 10 years earlier onset → 5-10 years off life expectancy)
Atlas connections: this island pulls together endocrine/metabolic-syndrome L4 + carbs-fiber/glycogen + fructose-metabolism + UPF + exercise / protein and a dozen other stories into a single clinical scenario.
Diagnostic criteria (ADA + Chinese Diabetes Society):
HbA1c ≥ 6.5% (glycated hemoglobin, reflects 3-month average glucose)or fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL) × two occasionsor OGTT 2 h glucose ≥ 11.1 mmol/L (200 mg/dL)or random glucose ≥ 11.1 mmol/L + hyperglycemia symptoms
Prediabetes:
HbA1c 5.7-6.4%or fasting 5.6-6.9 mmol/L (100-125 mg/dL, IFG)or OGTT 2 h 7.8-11.0 mmol/L (IGT)about 5-10% per year progress to T2D, but reversible
Epidemiology (China, IDF 2021 + Wang 2017 JAMA):
T2D prevalence 11.2% (~ 140 million patients), the largest in the worldprediabetes 35-50% (400-500 million nationwide)undiagnosed rate 50%+ — half of T2D patients do not know they have itannual healthcare cost ~ 200 billion CNY
Asian-phenotype specificities:
At the same BMI, T2D risk is 2-3× higher vs Europeans (Hu 2011 Lancet)"Lean T2D" — BMI < 25 can still develop disease; Asian diagnostic cutoffs should be at lower BMI (China ≥ 24 = overweight, vs Western ≥ 25)Mechanism: at the same BMI, visceral fat + insulin resistance + β-cell decline are all more pronounced
"Diabetes = a disease of the elderly" no longer holds:
T2D prevalence in Chinese 20-39 y/o is 5-8% (2020)Pediatric and adolescent T2D is rising sharply with obesity + UPFEarly-onset T2D has a larger lifespan impact (every 10 years earlier onset → 5-10 years off life expectancy)
Atlas connections: this island pulls together endocrine/metabolic-syndrome L4 + carbs-fiber/glycogen + fructose-metabolism + UPF + exercise / protein and a dozen other stories into a single clinical scenario.
Chapter 2
IR · 3 pathways
IR · 3 pathways
The plain version first: insulin is the "key" that lets blood sugar into your cells; insulin resistance means the cells go deaf to that key, so the body makes more and more insulin until the "key factory" (β-cells) burns out. Below is why the cells go deaf.
Insulin resistance (IR) sits at the core of T2D pathophysiology. The endocrine/metabolic-syndrome L4 covers it in detail; here is the condensed version:
Normal insulin signaling:
```
insulin → receptor → IRS-1 → PI3K → Akt → GLUT4 → glucose into cell
```
In IR, IRS-1 Ser307 is mis-phosphorylated → the entire downstream cascade is weakened.
Three upstream drivers (mutually reinforcing):
① Lipid (lipotoxicity):
Visceral adipose tissue (VAT) → releases FFA → ectopic lipid accumulation in muscle + liver + β-cellsDiacylglycerol (DAG) + ceramide → activate PKCθ + JNK → phosphorylate IRS-1 Ser307 → signal blockThe fructose DNL pathway (atlas fructose-metabolism) is upstream of this step
② Inflammation:
VAT releases tumor necrosis factor alpha: A strong pro-inflammatory signal molecule that runs high in chronic inflammation. / interleukin-6: A pro-inflammatory signal molecule (cytokine) released by immune cells during inflammation. / leptin / resistin → low-grade systemic chronic inflammationMacrophage infiltration of adipose tissue (M1 polarization)nuclear factor kappa B: The cell's inflammation master switch (a transcription factor) — when flipped, it turns inflammation on. activation → IRS-1 Ser phosphorylation → signal block
③ Androgen / sex-hormone imbalance:
PCOS women: androgens ↑ → worsens IR (see atlas PCOS L4)Men with low T (middle-aged abdominal obesity) → also promotes IR (bidirectional)SHBG ↓ is a marker of IR + MetSyn
β-cell decompensation:
Early: β-cells secrete 2-3× more insulin compensatorily → glucose stays normal → but insulin is already elevatedMiddle: β-cell function declines + cell number falls → impaired glucose tolerance → prediabetesLate: β-cell function < 50% → diabetes → some require exogenous insulin
Key insights:
"Diabetes = eating too much sugar" is a wrong simplification — the real cause is lipid + inflammation + hormonal systemic metabolic imbalance → β-cell decompensationHbA1c is the result, not the cause — treating by HbA1c alone is insufficient; look upstream (weight / VAT / FFA / inflammation)Early-stage reversibility: prediabetes + early T2D (HbA1c < 7.5, < 5 years) → 10-15% weight loss can produce substantial remission
Insulin resistance (IR) sits at the core of T2D pathophysiology. The endocrine/metabolic-syndrome L4 covers it in detail; here is the condensed version:
Normal insulin signaling:
```
insulin → receptor → IRS-1 → PI3K → Akt → GLUT4 → glucose into cell
```
In IR, IRS-1 Ser307 is mis-phosphorylated → the entire downstream cascade is weakened.
Three upstream drivers (mutually reinforcing):
① Lipid (lipotoxicity):
Visceral adipose tissue (VAT) → releases FFA → ectopic lipid accumulation in muscle + liver + β-cellsDiacylglycerol (DAG) + ceramide → activate PKCθ + JNK → phosphorylate IRS-1 Ser307 → signal blockThe fructose DNL pathway (atlas fructose-metabolism) is upstream of this step
② Inflammation:
VAT releases tumor necrosis factor alpha: A strong pro-inflammatory signal molecule that runs high in chronic inflammation. / interleukin-6: A pro-inflammatory signal molecule (cytokine) released by immune cells during inflammation. / leptin / resistin → low-grade systemic chronic inflammationMacrophage infiltration of adipose tissue (M1 polarization)nuclear factor kappa B: The cell's inflammation master switch (a transcription factor) — when flipped, it turns inflammation on. activation → IRS-1 Ser phosphorylation → signal block
③ Androgen / sex-hormone imbalance:
PCOS women: androgens ↑ → worsens IR (see atlas PCOS L4)Men with low T (middle-aged abdominal obesity) → also promotes IR (bidirectional)SHBG ↓ is a marker of IR + MetSyn
β-cell decompensation:
Early: β-cells secrete 2-3× more insulin compensatorily → glucose stays normal → but insulin is already elevatedMiddle: β-cell function declines + cell number falls → impaired glucose tolerance → prediabetesLate: β-cell function < 50% → diabetes → some require exogenous insulin
Key insights:
"Diabetes = eating too much sugar" is a wrong simplification — the real cause is lipid + inflammation + hormonal systemic metabolic imbalance → β-cell decompensationHbA1c is the result, not the cause — treating by HbA1c alone is insufficient; look upstream (weight / VAT / FFA / inflammation)Early-stage reversibility: prediabetes + early T2D (HbA1c < 7.5, < 5 years) → 10-15% weight loss can produce substantial remission
Lab interpretation
HbA1c (glycated hemoglobin):Reflects average glucose over the past 8-12 weeks (set by red cell lifespan)Pros: no fasting needed, single blood draw, stableLimits: anemia / abnormal hemoglobin (thalassemia / sickle): falsely lowIron deficiency / B12 deficiency: falsely highChronic kidney disease: unreliable
Fasting plasma glucose (FPG):
8+ hours fastingReflects hepatic glucose output + basal insulin resistance"Dawn phenomenon": early-morning cortisol + growth hormone → hepatic glucose ↑ → fasting reading elevated
OGTT (oral glucose tolerance test):
Fast + drink 75 g anhydrous glucose + retest at 2 hMost sensitive — catches early IR presentation (postprandial spikes)Some people have normal HbA1c + FPG but abnormal OGTT — important early signalRecommendation: 35+ y/o + any MetSyn marker, every 3 years
Insulin + C-peptide:
Fasting insulin > 12 µIU/mL suggests IR (Reaven 1988)HOMA-IR = (fasting insulin × fasting glucose) / 22.5; ≥ 2.5 suggests IRC-peptide reflects endogenous β-cell secretion; useful in insulin-treated patients to assess residual function
CGM (continuous glucose monitoring):
24-hour continuous subcutaneous interstitial glucose"Normal HbA1c" + high GI postprandial peaks → early IRMassive individual variation: the same banana + milk produces totally different glucose responses across peopleNew tool: 1-2 weeks of CGM can help healthy people understand their personal food responses
Self-check checklist (priority 35+ y/o):
Annually: HbA1c + fasting + waist + lipids + ALTAny abnormality: + OGTT + insulin + C-peptide"This year's check-up is normal" ≠ "next year will still be normal" — early-onset T2D forms over 5-10 years
Chapter 3
DiRECT · T2D reversibility
DiRECT · T2D reversibility
The DiRECT trial (Lean et al 2018 Lancet) is one of the most important RCTs in the atlas's cardiovascular + diabetes series — the first proof that T2D can be put into remission.
Design:
49 primary-care clinics in Scotland + EnglandN = 298 T2D patients (diagnosed ≤ 6 years, BMI 27-45, not insulin-dependent)Randomised: Very-low-calorie diet (VLCD) protocol vs standard care
VLCD protocol:
3-5 months: 825-853 kcal/day (protein shakes + vitamins)Refeeding phase: gradual reintroduction of solid food (2-8 weeks)Long-term maintenance: monthly dietitian follow-up + weight-maintenance strategy
Results (1 year):
46% T2D remission (HbA1c < 6.5%, off medication)vs standard-care 4% remissionAverage weight loss 10 kg (VLCD vs 1 kg control)Those losing ≥ 15 kg: 86% remissionThose losing 10-15 kg: 57% remission
Results (2 years, follow-up):
36% maintained remission (vs 3% standard care)Sustained remitters had fewer medications + improved cardiovascular markers + greatly improved quality of life
Results (5 years, 2024 update):
About 1/3 of remitters maintained remission — weight regain is the main cause of relapseNon-remitters who lost weight: still had substantially reduced cardiovascular risk
Mechanism (twin-cycle hypothesis, Lim 2011):
Excess weight → ectopic lipid (liver + pancreas) → β-cell function suppression + hepatic glucose output ↑Major weight loss → rapid depletion of ectopic lipid → β-cell recovery + liver normalisationEarly T2D (< 6-8 years) is reversible by this process; long-standing T2D has too much β-cell death → irreversible
Clinical translation:
UK NHS adopted the DiRECT protocol in 2020 as a standard option for early T2DSome Chinese hospitals run similar programs, but insurance coverage + dietitian resources are the implementation bottleneckKey point: this is not "dieting" — it is "structured medical nutrition therapy + long-term follow-up"; losing weight on your own ≠ DiRECT
Mediterranean diet + exercise (PREDIMED 2018, Look AHEAD 2013):
Slower weight loss than VLCD but more sustainablePREDIMED: Mediterranean + olive oil / nuts → cardiovascular events -30%Suited to populations who cannot do VLCD
Conclusion: the old view that T2D is "chronically progressive and irreversible" has been falsified — early stage + weight loss = real remission is possible.
Design:
49 primary-care clinics in Scotland + EnglandN = 298 T2D patients (diagnosed ≤ 6 years, BMI 27-45, not insulin-dependent)Randomised: Very-low-calorie diet (VLCD) protocol vs standard care
VLCD protocol:
3-5 months: 825-853 kcal/day (protein shakes + vitamins)Refeeding phase: gradual reintroduction of solid food (2-8 weeks)Long-term maintenance: monthly dietitian follow-up + weight-maintenance strategy
Results (1 year):
46% T2D remission (HbA1c < 6.5%, off medication)vs standard-care 4% remissionAverage weight loss 10 kg (VLCD vs 1 kg control)Those losing ≥ 15 kg: 86% remissionThose losing 10-15 kg: 57% remission
Results (2 years, follow-up):
36% maintained remission (vs 3% standard care)Sustained remitters had fewer medications + improved cardiovascular markers + greatly improved quality of life
Results (5 years, 2024 update):
About 1/3 of remitters maintained remission — weight regain is the main cause of relapseNon-remitters who lost weight: still had substantially reduced cardiovascular risk
Mechanism (twin-cycle hypothesis, Lim 2011):
Excess weight → ectopic lipid (liver + pancreas) → β-cell function suppression + hepatic glucose output ↑Major weight loss → rapid depletion of ectopic lipid → β-cell recovery + liver normalisationEarly T2D (< 6-8 years) is reversible by this process; long-standing T2D has too much β-cell death → irreversible
Clinical translation:
UK NHS adopted the DiRECT protocol in 2020 as a standard option for early T2DSome Chinese hospitals run similar programs, but insurance coverage + dietitian resources are the implementation bottleneckKey point: this is not "dieting" — it is "structured medical nutrition therapy + long-term follow-up"; losing weight on your own ≠ DiRECT
Mediterranean diet + exercise (PREDIMED 2018, Look AHEAD 2013):
Slower weight loss than VLCD but more sustainablePREDIMED: Mediterranean + olive oil / nuts → cardiovascular events -30%Suited to populations who cannot do VLCD
Conclusion: the old view that T2D is "chronically progressive and irreversible" has been falsified — early stage + weight loss = real remission is possible.
Chapter 4
Meds · GLP-1 era
Meds · GLP-1 era
T2D drug landscape by mechanism (2024-2025 consensus):
First-line: Metformin:
Invented 1957, US launch 1995, 60+ years of safety dataMechanism: AMP-activated protein kinase: The cell's 'low fuel' sensor — switches on when energy is low to make energy and pause building. activation + suppression of hepatic glucose output + improved IR (see atlas berberine L4 for the head-to-head)HbA1c ↓ 1-2%Side effects: GI (~ 25%, extended-release improves it) + long-term B12 deficiency (see atlas vitamin-b12)Price: ¥4-15/month, globally available
Second-line option 1: glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. receptor agonists (Liraglutide / Semaglutide / Tirzepatide):
Ozempic (semaglutide, since 2017) / Wegovy (weight-loss version) / Mounjaro (tirzepatide, GLP-1 + GIP, 2022)Mechanism: delayed gastric emptying + central satiety + β-cell insulin secretion + glucagon suppressionHbA1c ↓ 1-2% + weight ↓ 10-20% over 12-24 monthsAdditional hard-endpoint benefits: atherosclerotic cardiovascular disease: The plaque-clogged-artery family of disease — heart attack, stroke, peripheral artery disease. secondary prevention, heart failure, chronic kidney disease protection (SUSTAIN-6, REWIND, LEADER, etc.)2024 STEP-HFpEF, FLOW: significant reductions in all-cause + cardiovascular mortalitySide effects: GI (nausea / vomiting, 20-40%) + rare pancreatitisPrice: ¥800-1500/month, partial Chinese reimbursement; USA $700-1200/month
SGLT2 inhibitors (Empagliflozin / Dapagliflozin / Canagliflozin):
Inhibit renal glucose reabsorption → urinary glucose loss + weight loss + cardiovascular protectionHbA1c ↓ 0.7-1.0% + weight ↓ 2-3 kgEMPA-REG / DAPA-HF / DAPA-CKD: ↓ HF hospitalisation, ↓ CKD progressionSide effects: UTI + rare DKA (diabetic ketoacidosis)Important: used not only for T2D but also for non-diabetic HF + CKD
Others: sulfonylureas (hypoglycemia-prone, fading from first-line) / DPP-4 inhibitors (moderate efficacy, safe) / thiazolidinediones (Pioglitazone, fat-reducing + weight-increasing) / acarbose (postprandial) / insulin (later line)
Major 2024 consensus shift:
GLP-1 / SGLT2 have shifted from "T2D drugs" to "comprehensive cardiometabolic protective agents"A growing number of RCTs show benefit in non-diabetic obesity / HF / CKD patientsControversies: long-term safety? GLP-1 + sarcopenia (muscle loss) + price + post-discontinuation rebound
Debunking "Berberine = Nature's Ozempic" (covered in atlas berberine):
Berberine -2-5% body weight vs GLP-1 -15-20% — 3-5× difference, not comparableBerberine is a metformin alternative, not a GLP-1 alternative
Natural intervention vs drugs:
DiRECT 10-15 kg weight loss ≈ semaglutide weight-loss magnitudeBut DiRECT requires strict protocol + dietitian + a lot of effortDrugs are easier but more expensive + have less long-term dataBest combined: drug to initiate + lifestyle to maintain
First-line: Metformin:
Invented 1957, US launch 1995, 60+ years of safety dataMechanism: AMP-activated protein kinase: The cell's 'low fuel' sensor — switches on when energy is low to make energy and pause building. activation + suppression of hepatic glucose output + improved IR (see atlas berberine L4 for the head-to-head)HbA1c ↓ 1-2%Side effects: GI (~ 25%, extended-release improves it) + long-term B12 deficiency (see atlas vitamin-b12)Price: ¥4-15/month, globally available
Second-line option 1: glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. receptor agonists (Liraglutide / Semaglutide / Tirzepatide):
Ozempic (semaglutide, since 2017) / Wegovy (weight-loss version) / Mounjaro (tirzepatide, GLP-1 + GIP, 2022)Mechanism: delayed gastric emptying + central satiety + β-cell insulin secretion + glucagon suppressionHbA1c ↓ 1-2% + weight ↓ 10-20% over 12-24 monthsAdditional hard-endpoint benefits: atherosclerotic cardiovascular disease: The plaque-clogged-artery family of disease — heart attack, stroke, peripheral artery disease. secondary prevention, heart failure, chronic kidney disease protection (SUSTAIN-6, REWIND, LEADER, etc.)2024 STEP-HFpEF, FLOW: significant reductions in all-cause + cardiovascular mortalitySide effects: GI (nausea / vomiting, 20-40%) + rare pancreatitisPrice: ¥800-1500/month, partial Chinese reimbursement; USA $700-1200/month
SGLT2 inhibitors (Empagliflozin / Dapagliflozin / Canagliflozin):
Inhibit renal glucose reabsorption → urinary glucose loss + weight loss + cardiovascular protectionHbA1c ↓ 0.7-1.0% + weight ↓ 2-3 kgEMPA-REG / DAPA-HF / DAPA-CKD: ↓ HF hospitalisation, ↓ CKD progressionSide effects: UTI + rare DKA (diabetic ketoacidosis)Important: used not only for T2D but also for non-diabetic HF + CKD
Others: sulfonylureas (hypoglycemia-prone, fading from first-line) / DPP-4 inhibitors (moderate efficacy, safe) / thiazolidinediones (Pioglitazone, fat-reducing + weight-increasing) / acarbose (postprandial) / insulin (later line)
Major 2024 consensus shift:
GLP-1 / SGLT2 have shifted from "T2D drugs" to "comprehensive cardiometabolic protective agents"A growing number of RCTs show benefit in non-diabetic obesity / HF / CKD patientsControversies: long-term safety? GLP-1 + sarcopenia (muscle loss) + price + post-discontinuation rebound
Debunking "Berberine = Nature's Ozempic" (covered in atlas berberine):
Berberine -2-5% body weight vs GLP-1 -15-20% — 3-5× difference, not comparableBerberine is a metformin alternative, not a GLP-1 alternative
Natural intervention vs drugs:
DiRECT 10-15 kg weight loss ≈ semaglutide weight-loss magnitudeBut DiRECT requires strict protocol + dietitian + a lot of effortDrugs are easier but more expensive + have less long-term dataBest combined: drug to initiate + lifestyle to maintain
Chapter 5
Decision tree
Decision tree
🚩 Safety first · when to seek emergency care
Diabetes has several acute emergencies — get emergency care immediately (do not wait) if you have:
Diabetic ketoacidosis (DKA): thirst / frequent urination + nausea & vomiting + abdominal pain + deep rapid or "fruity"-smelling breath + confusionSevere hypoglycemia: cold sweat / shaking / palpitations / altered consciousness / seizure — if awake and able to swallow, take 15 g of fast sugar now; if it does not improve or consciousness is impaired, call an ambulanceHyperosmolar hyperglycemic state (HHS): extreme thirst + heavy urination + drowsiness / altered consciousness (more common in older adults)
The safety floor on meds and diet: any starting, changing, or stopping of medication must be discussed with your doctor first; a very-low-calorie diet (like the DiRECT ~825 kcal) must be done under medical + dietitian supervision — it can put early patients into remission, but it is not a do-it-yourself-at-home plan.
---
"I have prediabetes / T2D — what do I do?" — a decision path:
Q1: What stage are you in?
HbA1c 5.7-6.4%: prediabetes — golden window, focus on lifestyleHbA1c 6.5-7.5% + < 6 years duration: early T2D — DiRECT remission candidateHbA1c 7.5-9% + 5-10 years duration: mid-stage — lifestyle + medication (start with metformin)HbA1c > 9% / > 10 years duration / serious complications: multi-drug combinations + possibly insulin
Q2: What is your goal?
Remission (off medication): for early patients, 10-15 kg weight loss is the strongest interventionControl (maintain HbA1c < 7%): most patients, drugs + lifestyle combinedReduce complications + longevity: focus on cardiovascular + renal + retinal protection
Q3: What is your weight and capacity for weight loss?
Can do strict weight loss (time + resources): DiRECT protocol + dietitian + long-term supportModerate weight loss (5-10% target): Mediterranean diet + strength training + walkingDifficulty losing weight (psychological / time / appetite): consider glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. (if indicated)
Q4: Drug choice:
First-line: metformin (unless contraindicated)Second-line + cardiovascular disease / HF / CKD: GLP-1 or SGLT2 (hard-endpoint benefit)Second-line + main goal is weight loss: GLP-1Second-line + high postprandial glucose: acarbose / SGLT2Third-line: multi-drug combinations + insulin
Core intervention list (do at any stage):
Cut sugar-sweetened beverages + milk tea (atlas SSDs chapter — single highest-ROI move)30 minutes aerobic daily + 2-3 strength sessions per weekVegetables and protein first, carbs last at each meal (Shukla 2015)No eating after 10 PM + 7-8 hours sleepStop smoking + limit alcohol (alcohol + T2D = severe acceleration of hepatic complications)B12 monitoring (annually if on metformin)
Mental health + diabetes:
T2D + depression comorbidity rate 30-40%"Diabetes distress" — treatment burden + self-blame + anxietyIt is not "lack of self-discipline"; it is the psychological burden of a chronic illness — deserves psychological support
Self-management tools:
Continuous glucose monitor (CGM): 1-2 weeks can help understand personal food responsesApps: ADA-recommended in the US; Dingxiang Doctor / Tang Hu Shi in ChinaCommunity support: patient groups + dietitians + endocrinologists
Closing the loop with other atlas stories:
endocrine/metabolic-syndrome L4 (5-step reversibility mechanism)carbs-fiber/glycogen L4 (GLUT4 + insulin signaling)fructose-metabolism + UPF + alcohol (dietary drivers)sleep-apnea + insomnia + shift-work-circadian (sleep drivers)hashimoto / pcos (other endocrine comorbidities)exercise + protein + strength training (Batch IV)These 12 stories converge on this one condition island to form a complete teaching path
Atlas position: T2D is not the destiny tied to the label "diabetes" — it is a state of the metabolic system, and in most early / mid-stage patients it is interveneable and improvable. The atlas gives you mechanism + evidence so you can understand your own metabolism and decide together with your doctor (it does not replace medical care).
Diabetes has several acute emergencies — get emergency care immediately (do not wait) if you have:
Diabetic ketoacidosis (DKA): thirst / frequent urination + nausea & vomiting + abdominal pain + deep rapid or "fruity"-smelling breath + confusionSevere hypoglycemia: cold sweat / shaking / palpitations / altered consciousness / seizure — if awake and able to swallow, take 15 g of fast sugar now; if it does not improve or consciousness is impaired, call an ambulanceHyperosmolar hyperglycemic state (HHS): extreme thirst + heavy urination + drowsiness / altered consciousness (more common in older adults)
The safety floor on meds and diet: any starting, changing, or stopping of medication must be discussed with your doctor first; a very-low-calorie diet (like the DiRECT ~825 kcal) must be done under medical + dietitian supervision — it can put early patients into remission, but it is not a do-it-yourself-at-home plan.
---
"I have prediabetes / T2D — what do I do?" — a decision path:
Q1: What stage are you in?
HbA1c 5.7-6.4%: prediabetes — golden window, focus on lifestyleHbA1c 6.5-7.5% + < 6 years duration: early T2D — DiRECT remission candidateHbA1c 7.5-9% + 5-10 years duration: mid-stage — lifestyle + medication (start with metformin)HbA1c > 9% / > 10 years duration / serious complications: multi-drug combinations + possibly insulin
Q2: What is your goal?
Remission (off medication): for early patients, 10-15 kg weight loss is the strongest interventionControl (maintain HbA1c < 7%): most patients, drugs + lifestyle combinedReduce complications + longevity: focus on cardiovascular + renal + retinal protection
Q3: What is your weight and capacity for weight loss?
Can do strict weight loss (time + resources): DiRECT protocol + dietitian + long-term supportModerate weight loss (5-10% target): Mediterranean diet + strength training + walkingDifficulty losing weight (psychological / time / appetite): consider glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. (if indicated)
Q4: Drug choice:
First-line: metformin (unless contraindicated)Second-line + cardiovascular disease / HF / CKD: GLP-1 or SGLT2 (hard-endpoint benefit)Second-line + main goal is weight loss: GLP-1Second-line + high postprandial glucose: acarbose / SGLT2Third-line: multi-drug combinations + insulin
Core intervention list (do at any stage):
Cut sugar-sweetened beverages + milk tea (atlas SSDs chapter — single highest-ROI move)30 minutes aerobic daily + 2-3 strength sessions per weekVegetables and protein first, carbs last at each meal (Shukla 2015)No eating after 10 PM + 7-8 hours sleepStop smoking + limit alcohol (alcohol + T2D = severe acceleration of hepatic complications)B12 monitoring (annually if on metformin)
Mental health + diabetes:
T2D + depression comorbidity rate 30-40%"Diabetes distress" — treatment burden + self-blame + anxietyIt is not "lack of self-discipline"; it is the psychological burden of a chronic illness — deserves psychological support
Self-management tools:
Continuous glucose monitor (CGM): 1-2 weeks can help understand personal food responsesApps: ADA-recommended in the US; Dingxiang Doctor / Tang Hu Shi in ChinaCommunity support: patient groups + dietitians + endocrinologists
Closing the loop with other atlas stories:
endocrine/metabolic-syndrome L4 (5-step reversibility mechanism)carbs-fiber/glycogen L4 (GLUT4 + insulin signaling)fructose-metabolism + UPF + alcohol (dietary drivers)sleep-apnea + insomnia + shift-work-circadian (sleep drivers)hashimoto / pcos (other endocrine comorbidities)exercise + protein + strength training (Batch IV)These 12 stories converge on this one condition island to form a complete teaching path
Atlas position: T2D is not the destiny tied to the label "diabetes" — it is a state of the metabolic system, and in most early / mid-stage patients it is interveneable and improvable. The atlas gives you mechanism + evidence so you can understand your own metabolism and decide together with your doctor (it does not replace medical care).
GLP-1 RA · mechanism + RCTs
The biggest revolution in diabetes care since 2015 — two classes of glucose-lowering drugs with simultaneous "cardiovascular / renal hard-endpoint" benefits have changed the treatment hierarchy. First, glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar..GLP-1 receptor agonists (Glucagon-Like Peptide-1 RA):
Semaglutide (Ozempic / Wegovy) — weekly injection / oralLiraglutide (Victoza) — daily injectionDulaglutide (Trulicity) — weekly injectionTirzepatide (Mounjaro / Zepbound) — dual GLP-1 + GIP agonist, weekly injection, available in China from 2024
Mechanism (5 pathways):
Pancreatic β-cells: glucose-dependent insulin secretion ↑ (very low hypoglycemia risk)Pancreatic α-cells: glucagon ↓Stomach: delayed emptying → smoother postprandial glucose + stronger satietyHypothalamus: appetite center ↓Cardiovascular + renal: direct protection (mechanism not fully attributable to glucose lowering)
Key RCTs:
LEADER (Liraglutide): MACE ↓ 13% / CV death ↓ 22% / all-cause death ↓ 15%SUSTAIN-6 (Semaglutide): MACE ↓ 26%STEP-1 (Semaglutide 2.4 mg for weight loss): weight ↓ 14.9% over 68 weeks (Wegovy indication)SURMOUNT-1 (Tirzepatide): weight ↓ 22.5% over 72 weeks (strongest weight-loss drug to date)SELECT (Semaglutide cardiovascular, non-diabetic): MACE ↓ 20% — pushes GLP-1 into the "anti-cardiovascular disease drug" category
Side effects:
GI: nausea (30-40% on initiation) + vomiting + constipation + diarrhea — dose titration + time to adaptMedullary thyroid carcinoma warning (rodent data, no confirmed human signal): contraindicated in MTC / MEN2 family historyPancreatitis risk: small relative increase, low absolute riskGallstones: associated with rapid weight lossMuscle loss ~ 20-40% of lost weight is lean mass — see atlas sarcopenia warning
SGLT2 + ADA 2024 order
SGLT2 inhibitors (Sodium-Glucose Co-transporter 2):Dapagliflozin (Farxiga)Empagliflozin (Jardiance)Canagliflozin (Invokana)
Mechanism: blocks glucose reabsorption in the renal proximal tubule → urinary glucose loss ~ 80-100 g/day → glucose ↓ + ~ 300 kcal/day calorie loss
Unexpected benefits: HF + renal protection (mechanism not fully attributable to glucose lowering)
Key RCTs:
EMPA-REG (Empagliflozin): CV death ↓ 38%, HF hospitalisation ↓ 35%DAPA-HF (Dapagliflozin in HF, non-diabetic): HF worsening ↓ 26% — SGLT2 also becomes an HF drugDAPA-CKD: CKD progression ↓ 39% — SGLT2 also becomes a kidney-disease drug
Side effects:
Genital candidiasis (high urinary glucose): women 10-20% / men 2-5%UTI slightly ↑Ketoacidosis (DKA): rare; vigilance in T1D / very-low-carb diet usersAmputation risk (canagliflozin CANVAS): slight ↑, follow-up evidence neutral
T2D treatment order (ADA 2024):
First-line: metformin (unless contraindicated)Second-line (with cardiovascular / renal / HF comorbidity): glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. or SGLT2 (choose by comorbidity, no longer by HbA1c alone)Second-line (primary need is weight loss): GLP-1 (especially semaglutide / tirzepatide)Third-line: multi-drug combinations, potentially insulin later
Pricing + GLP-1 miracle-drug caveats
Price + accessibility (China 2024-2025):Semaglutide (Nuotai): ¥800-1200/month, partial reimbursement from 2024Tirzepatide (Duyida): launched 2024, not yet reimbursed, ¥1500-3000/monthDomestic SGLT2 (Hengrui / Innovent / Fosun): substantially cheaper, ¥30-100/month, reimbursement covered
Risks of the "glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. miracle weight-loss drug" narrative:
Rebound after discontinuation: STEP-4 shows that 1 year after stopping, 67% of lost weight is regainedMuscle loss: ~ 25% of lost weight is lean mass — must be paired with strength training + high proteinLong-term (10+ year) safety data still accumulating"Influencer / cross-border purchase" risks: counterfeit + dose errors + no medical oversight — strong warning
Atlas closure: endocrine/metabolic-syndrome + sarcopenia (GLP-1 + protein + strength) + DiRECT (weight-loss remission) + obesity / weight-loss island.